EUCTR2014-002224-26-NL进行中（未招募）不适用
A new dosing strategy of infliximab versus standard dosing in patients with severe sarcoidosis: optimization of treatment - Concentration guided dosing of infliximab in sarcoidosis
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •patients diagnosed with sarcoidosis being treated with infliximab or with an indication for infliximab
- •capability of giving informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 70
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •vaccination with live viral or bacterial vaccines within the previous 3 months, or with the last dose within the previous 3 months
- •active or untreated latent tuberculosis (by mantoux-Elispot/TBC-IGRA)
- •serious infections within the last 2 months
- •serious right ventricular heart failure or cor polmunale
- •Active hepatitis B
- •history of allergic reactions to monocolonal antibodies or their fragments
- •oppotunistic infections with the last 6 months
- •transplantation
- •known malignancy
- •pregnancy or breastfeeding
研究者
相似试验
撤回
4 期
A new dosing strategy of infliximab versus standard dosing in patients with severe sarcoidosis: optimization of treatment1002766510024967SarcoidosisNL-OMON42033Sint Antonius Ziekenhuis70
进行中（未招募）
不适用
A Study of Dose Optimization of Infliximab in the Treatment of Moderate to Severe Plaque Psoriasis. - DOSEModerate to severe plaque PsoriasisMedDRA version: 11.0Level: LLTClassification code 10037153Term: <Manually entered code. Term in E.1.1>EUCTR2008-000454-12-GRSchering Plough Research Institute, a Division of Schering Corporation200
进行中（未招募）
1 期
A Study of Dose Optimization of Infliximab in the Treatment of Moderate to Severe Plaque Psoriasis. - DOSEModerate to severe plaque PsoriasisMedDRA version: 11.0Level: LLTClassification code 10037153Term: <Manually entered code. Term in E.1.1>EUCTR2008-000454-12-HUSchering Plough Research Institute, a Division of Schering Corporation200
进行中（未招募）
不适用
A Study of Dose Optimization of Infliximab in the Treatment of Moderate to Severe Plaque Psoriasis. - DOSEEUCTR2008-000454-12-DESchering Plough Research Institute, a Division of Schering Corporation200
进行中（未招募）
不适用
A Study of Dose Optimization of Infliximab in the Treatment of Moderate to Severe Plaque Psoriasis. - DOSEEUCTR2008-000454-12-GBSchering Plough Research Institute, a Division of Schering Corporation200